New pill cocktail shows promise for Hard-to-Treat breast cancer
NCT ID NCT05573555
First seen Mar 19, 2026 · Last updated May 16, 2026 · Updated 9 times
Summary
This study tests a new oral drug, ARV-471, combined with ribociclib in people with advanced or metastatic ER+ breast cancer that no longer responds to prior treatments. About 20 adults will take both pills daily at home. Researchers will check safety and whether tumors shrink. The goal is to control the cancer, not cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
BC Cancer Vancouver
Vancouver, British Columbia, V5Z 1H7, Canada
-
BC Cancer Vancouver
Vancouver, British Columbia, V5Z 4E6, Canada
-
Barnes Jewish Hospital Department of Laboratories
St Louis, Missouri, 63110, United States
-
Barnes Jewish Hospital Lab- South County
St Louis, Missouri, 63129, United States
-
Barnes-Jewish Hospital
St Louis, Missouri, 63110, United States
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
-
CIUSSS- saguenay-Lac-Saint-Jean
Chicoutimi, Quebec, G7H 5H6, Canada
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Dana-Farber Cancer Institute - Chestnut Hill
Newton, Massachusetts, 02459, United States
-
Fondazione IRCCS San Gerardo dei Tintori
Monza, Lombardy, 20900, Italy
-
Hospital Universitario 12 de Octubre
Madrid, Madrid, Comunidad de, 28041, Spain
-
Hospital Universitario Virgen Del Rocio
Seville, 41013, Spain
-
Jewish General Hospital
Montreal, Quebec, H3T 1E2, Canada
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Moffitt Cancer Center - International Plaza
Tampa, Florida, 33607, United States
-
Moffitt Cancer Center, Richard M. Shulze Family Foundation Outpatient Center
Tampa, Florida, 33612, United States
-
Moffitt McKinley Hospital
Tampa, Florida, 33612, United States
-
Siteman Cancer Center
St Louis, Missouri, 63108, United States
-
Siteman Cancer Center - North County
Florissant, Missouri, 63031, United States
-
Siteman Cancer Center - South County
St Louis, Missouri, 63129, United States
-
Siteman Cancer Center - St Peters
City of Saint Peters, Missouri, 63376, United States
-
Siteman Cancer Center - WUPI
Shiloh, Illinois, 62269, United States
-
Siteman Cancer Center - West County
Creve Coeur, Missouri, 63141, United States
-
Stanford Women's Cancer Center
Palo Alto, California, 94304, United States
-
Sunnybrook Research Institute
Toronto, Ontario, M4N 3M5, Canada
-
The Ottawa Hospital - General Campus
Ottawa, Ontario, K1H 8L6, Canada
-
UCSF Medical Center at Mission Bay
San Francisco, California, 94158, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
-
Washington University School of Medicine - Siteman Cancer Center
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.